Descriptive characteristics of patients with T2D during follow-up 1998–2014
| Patients with NF1 | Controls | Siblings without NF1 | |
| n | 19 | 779 | 83 |
| Sex | |||
| Female, n (%) | 14 (73.7) | 402 (51.6) | 42 (50.6) |
| Male, n (%) | 5 (26.3) | 377 (48.4) | 41 (49.4) |
| Age at first T2D-related encounter or drug purchase during follow-up, mean (SD) | 56.49 (17.45) | 58.64 (14.18) | 49.48 (12.63) |
| T2D-related encounters | |||
| Patients, n (%) | 7 (36.8) | 312 (40.1) | 27 (32.5) |
| Number/patient among those with at least one encounter, median (range) | 2 (1 to 8) | 2 (1 to 190) | 2 (1 to 504) |
| Purchases of insulins and analogues (ATC A10A) | |||
| Patients, n (%) | 6 (31.6) | 201 (25.8) | 17 (20.5) |
| Number/patient among those with at least one purchase, median (range) | 15 (2 to 22) | 17 (1 to 99) | 10 (1 to 85) |
| Purchases of other antidiabetic medication (ATC A10B) | |||
| Patients, n (%) | 17 (89.5) | 723 (92.8) | 76 (91.6) |
| Number/patient among those with at least one purchase, median (range) | 10 (1 to 81) | 18 (1 to 128) | 15 (1 to 104) |
| Special drug reimbursement for insulin, n (%) | 10 (52.6) | 554 (71.1) | 56 (67.5) |
ATC, Anatomical Therapeutic Chemical classification; NF1, neurofibromatosis type 1; T2D, type 2 diabetes.